20 January 2021

InVixa has entered into an exclusive licensing deal with the University of California, Davis, for commercialising inhaled statins to treat the SARS-CoV-2 virus. The deal allows InVixa the exclusive rights to commercialise its inhaled product for Covid-19 and other viral respiratory diseases.

Iraq‘s national authority for drug selection has approved UK’s AstraZeneca/University of Oxford and China’s Sinopharm Covid-19 vaccines for emergency use in the country. In late December, the Iraqi drug authority granted emergency authorisation to the Pfizer/BioNTech vaccine, with the first batch of the vaccine scheduled to arrive in February 2021.

Algernon Pharmaceuticals announced that the external Data and Safety Monitoring Board (DSMB) has reviewed the Phase 2b part of the company’s Phase 2b/3 human study of Ifenprodil (NP-120) for treating Covid-19. As a result, the board granted the company approval to continue with the Phase 3 part of its clinical study.

Rospotrebnadzor, Russia’s federal agency for consumer rights protection and wellbeing, announced that Russia’s second Covid-19 vaccine candidate EpiVacCorona proved to be 100% effective in its early-stage trials. The data of the Phase I and II trials were released before the commencement of the Phase III trial, which is scheduled to involve large number of participants and a placebo group.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.